Document is current
Any future updates will be listed below
-
Authors
Bianchini, Giampaolo https://orcid.org/0000-0002-6790-6267
De Angelis, Carmine
Licata, Luca
Gianni, Luca https://orcid.org/0000-0002-2372-9625
- License Information
-
More Information
Article History
Accepted: 20 September 2021
First Online: 9 November 2021
Competing interests
: G.B. is a consultant and/or advisory board member for Amgen, AstraZeneca, Chugai, Daiichi Sankyo, EISAI, Eli Lilly, Genomic Health, Merck Sharp & Dohme, Neopharm, Novartis, Pfizer, Roche and Sanofi. C.D.A. is a consultant and/or advisory board member for AstraZeneca, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and Roche. L.L. is a consultant for Eli Lilly and Novartis. L.G. is a consultant and/or advisory board member for ADC Therapeutics, Amgen, AstraZeneca, Biomedical Insights, Celgene, Eli Lilly, Forty Seven (CD47 programmes), G1 Therapeutics, GENENTA, Genentech, Genomic Health, Hexal Sandoz, Menarini Ricerche, Merck Sharp & Dohme, METIS Precision Medicine, Novartis, Odonate Therapeutics, Oncolytics Biotech, Onkaido Therapeutics, Pfizer, Revolution Medicines, Roche, Sanofi–Aventis, Seattle Genetics, Synaffix, Synthon, Taiho Pharmaceutical and Zymeworks.
